Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 17, 2026

References are made to the notice of the extraordinary general meeting (the "**EGM Notice**") and the circular (the "**EGM Circular**") of Abbisko Cayman Limited (the "**Company**") both dated August 28, 2026. Unless otherwise indicated, capitalised terms used herein have the same meanings as those defined in the EGM Circular.

POLL RESULTS OF EGM

The Board is pleased to announce that the extraordinary general meeting of the Company was held on September 17, 2026 (the "**EGM**"), and the proposed resolution set out in the EGM Notice was duly passed by the Shareholders by way of poll.

The poll results in respect of the resolution proposed at the EGM are as follows:

SPECIAL RESOLUTION		No. of Votes (%)*	
		For	Against
1.	subject to and conditional upon the approval of the Registrar of Companies in the Cayman Islands, the English name of the Company be changed from "Abbisko Cayman Limited" to "Abbisko Medicine Co., Ltd." and the dual foreign name in Chinese of the Company be changed from "和譽開曼有限責任公司" to "和譽醫藥有限責任公司" (collectively, the "**Change of Company Name**") with effect from the date of the certificate of incorporation on change of name issued by the Registrar of Companies in the Cayman Islands, and that any one of the directors of the Company be and is hereby authorized to do all such acts and things and execute all such documents, including under seal where appropriate, which he may consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the Change of Company Name and to attend to any necessary registration and/or filing for and on behalf of the Company.	416,227,695 (100.0000%)	0 (0.0000%)

* *All percentages are rounded to 4 decimal places.*

Shareholders may refer to the EGM Notice and EGM Circular for the full text of the above resolution.

As more than 75% of the votes were cast in favour of the above special resolution numbered 1, the above special resolution was duly passed as a special resolution of the Company.

GENERAL

As at the date of the EGM, the total number of issued Shares was 726,205,350 Shares. The trustee (who held 46,344,015 Shares under the 2019 Share Incentive Plan, the Post-IPO RSU Scheme and the Post-IPO Share Option Scheme in aggregate) was required to and had abstained from voting on the resolution proposed at the EGM. There were (i) 9,109,000 treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS), and (ii) 2,485,000 Shares repurchased by the Company which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the EGM. Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolutions at the EGM was 668,267,335. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required to abstain from voting at the EGM under the Listing Rules. No Shareholder had indicated in the EGM Circular that they intended to vote against or to abstain from voting on the resolution proposed at the EGM.

Dr. Xu Yao-Chang, the executive Director and the Chairman of the Board of the Company, presided at the EGM. The executive Directors of the Company, Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing, and the independent non-executive Directors of the Company, Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam attended the EGM in person or by electronic means.

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, September 17, 2026

As at the date of this announcement, the Board comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive Directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive Directors.